Glaukos Corporation recently reported its third quarter 2025 results, showing sales of US$133.54 million and a net loss of US$16.23 million, marking a strong improvement from the previous year; in addition, the company raised its full-year 2025 revenue guidance to US$490–495 million and issued a new preliminary outlook for 2026 revenue of US$600–620 million.

An important insight is that both quarterly and nine-month net losses were reduced by a substantial margin compared to the prior year, highlighting operational progress alongside top-line growth momentum.

We'll examine how Glaukos' improved financial performance and raised guidance may influence its business outlook and longer-term growth narrative.

These 13 companies survived and thrived after COVID and have the right ingredients to survive Trump's tariffs. Discover why before your portfolio feels the trade war pinch.

To be a shareholder of Glaukos, you need to believe in the transformational potential of interventional glaucoma therapies and the company’s pace of innovation with iDose TR and new corneal health products like Epioxa. The recent strong sales growth and lowered losses support optimism around product execution, but they do not materially change the biggest near-term catalyst, which remains broader payer reimbursement adoption, or address the persistent risk of reimbursement pressures from CMS or Medicare contractors.

The most relevant recent announcement is Glaukos’s raised full-year 2025 revenue guidance to US$490–495 million and its new preliminary outlook for 2026, signaling higher expected demand for its portfolio. This revised guidance reflects management’s confidence in the uptake of both existing and newly launched therapies, aligning with the key catalyst of expanding payer coverage and access for iDose and Epioxa.

However, investors should also be aware that if CMS reimbursement for ophthalmic procedures tightens unexpectedly, it could…

Read the full narrative on Glaukos (it's free!)

Glaukos' outlook anticipates $856.9 million in revenue and $72.3 million in earnings by 2028. This scenario assumes annual revenue growth of 25.6% and an earnings increase of $165.1 million from the current $-92.8 million level.

Uncover how Glaukos' forecasts yield a $119.85 fair value, a 43% upside to its current price.

Simply Wall St Community members’ fair value estimates for Glaukos range from US$74 to US$310 based on 4 different forecasts. Strong revenue growth expectations contrast with ongoing risks from reimbursement uncertainty, making it essential to consider multiple viewpoints before forming an opinion.

Explore 4 other fair value estimates on Glaukos - why the stock might be worth over 3x more than the current price!

Disagree with existing narratives? Create your own in under 3 minutes - extraordinary investment returns rarely come from following the herd.

A great starting point for your Glaukos research is our analysis highlighting 2 key rewards that could impact your investment decision.

Our free Glaukos research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Glaukos' overall financial health at a glance.

Our top stock finds are flying under the radar-for now. Get in early:

The end of cancer? These 29 emerging AI stocks are developing tech that will allow early identification of life changing diseases like cancer and Alzheimer's.

Uncover the next big thing with financially sound penny stocks that balance risk and reward.

Rare earth metals are an input to most high-tech devices, military and defence systems and electric vehicles. The global race is on to secure supply of these critical minerals. Beat the pack to uncover the 35 best rare earth metal stocks of the very few that mine this essential strategic resource.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Companies discussed in this article include GKOS.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com